The approved products and active Phase 2 and Phase 3 obesity and metabolic candidates we follow, spanning the GLP-1, GIP, glucagon, amylin and related pathways — with what each one targets, how far along it is, and what's genuinely coming next. Some programmes here are approved or filed outside the US (China, Korea) and have no US regulatory path yet; that is stated on each card. No compounded or grey-market products.
Last updated: Oct 8, 2026
Receptors: GLP-1GIPglucagonamylinNPY2UCN2 −GIP = antagonistStage: filled = reached, dark = currentBeyond weight loss: ✓ benefit ~ early signal ⚠ harm · untested
Results are not directly comparable unless duration, population and calculation method match — each figure carries its own below.
| Molecule | Maker | Targets | Stage | Mean weight change | What's next |
|---|---|---|---|---|---|
| tirzepatide Mounjaro (T2D), Zepbound (obesity, OSA) |  | GIPGLP-1 | ✓ Approved | 20.9%72 wk · obesity, no T2D · treatment-regimen · raw change | SURMOUNT-MMO (NCT05556512, n=15,374), the dedicated obesity cardiovascular-outcomes trial (2027-10) |
| semaglutide Ozempic (injectable, T2D), Wegovy (injectable, obesity, 2.4 mg), Wegovy HD (injectable, obesity, 7.2 mg), Wegovy pill (oral semaglutide, obesity), Rybelsus (oral, T2D) |  | GLP-1 | ✓ Approved | 18.7%72 wk · obesity, no T2D · treatment-policy · raw change | No FDA decision pending — MASH (Aug 2025), oral 25 mg (Dec 2025) and Wegovy HD 7.2 mg (Mar 2026) are all approved |
| orforglipron Foundayo | | GLP-1 | ✓ Approved | 11.2%72 wk · obesity, no T2D · treatment-regimen · raw change | Type 2 diabetes indication still pending |
| cagrilintide + semaglutide CagriSema | | GLP-1amylin | Filed (FDA review) | 20.4%68 wk · obesity, no T2D · treatment-policy · raw change | FDA decision for weight management expected in Q4 2026; REDEFINE 11 reads out Q1 2027 |
| retatrutide — | | GIPGLP-1glucagon | Phase 3 complete | 28.3%80 wk · obesity, no T2D · efficacy estimand · raw change | FDA submission (BLA) planned (2027-Q1) |
| ribupatide (KAI-9531 / HRS9531) — |  | GIPGLP-1 | Phase 3 | 23.6%36 wk · obesity · efficacy estimand · raw change | KaiNETIC global Phase 3 readouts; China NMPA filing submitted (2026-2027) |
| enicepatide (CT-388 / RO7795068) — |  | GIPGLP-1 | Phase 3 | 22.5%48 wk · obesity · efficacy estimand · placebo-adjusted | Phase 3 ENITH-1/ENITH-2 chronic weight management readouts; Phase 3 glycemic-control program + cardiovascular outcomes trials planned to start H1 2027 |
| amycretin (INN: zenagamtide) — | | amylinGLP-1 | Phase 3 | 22.0%36 wk · obesity, no T2D · raw change | AMAZE Phase 3 obesity readouts; separate type 2 diabetes Phase 3 planned (2026-H2) |
| eloralintide — | | amylin | Phase 3 | 20.1%48 wk · obesity · raw change | Lilly plans to start AMPLIFY, the Phase 3 programme for EloraTZP (a single-injection combination with tirzepatide), by the end of 2026; ENLIGHTEN Phase 3 readouts for eloralintide alone (obesity, type 2 diabetes, sleep apnea, knee osteoarthritis) follow in 2027-2028 |
| UBT251 — | The United Laboratories (China) / Novo Nordisk (rights outside Greater China) | GIPGLP-1glucagon | Phase 3 recruiting in China (type 2 diabetes); Phase 2 globally (Novo) | 19.7%24 wk · overweight/obesity, no T2D (China) · efficacy estimand · raw change | The semaglutide-controlled China Phase 2 in type 2 diabetes (NCT07163624), complete and still unreported; then Novo's own Phase 2 obesity dose-finding trial (NCT07395687), whose estimated primary completion is 14 Jan 2027 |
| VK2735 — |  | GIPGLP-1 | Phase 3 | 17.8%21 wk · obesity · raw change | Phase 3 VANQUISH-1 & -2 enrollment complete; topline expected ~2027. Part 2 of the maintenance study (tablets and less frequent injections) also reports in 2027 (2026) |
| mazdutide — | | glucagonGLP-1 | Approved · China | 16.65%60 wk · obesity, no T2D · raw change | 9 mg supplementary application under NMPA review (accepted 25 Nov 2025); still no US filing |
| aleniglipron (GSBR-1290) — |  | GLP-1 | Phase 3 (enrolling) | 16.3%44 wk · obesity · placebo-adjusted | Nearer-term: Q4 2026 readouts from the Phase 2 Body Composition trial (NCT07169942), Phase 2 T2DM trial (NCT07400588), and Phase 1 SWITCH trial (injectable-to-oral transition). Registrational: ACCOMPLISH-1 (NCT07654361, n=3,600) and ACCOMPLISH-2 (NCT07654374, n=1,100) — enrolling, topline data expected 2H 2028. |
| maridebart cafraglutide MariTide |  | GLP-1−GIP | Phase 3 | 16.2%52 wk · obesity, no T2D · treatment-policy · raw change | MARITIME Phase 3 program underway (2026) |
| berobenatide (MET-097i / PF-08653944) — |  | GLP-1 | Phase 3 | 14.1%28 wk · obesity · placebo-adjusted | VESPER-4 and the wider Phase 3 programme reading out (2027) |
| survodutide — |  | glucagonGLP-1 | Phase 3 | 13.0%76 wk · obesity, no T2D · treatment-regimen · raw change | SYNCHRONIZE-2 (diabetes) reported on 1 Oct 2026 in NEJM. One completed Phase 3 trial is still waiting to report: SYNCHRONIZE-CVOT (NCT06077864, n=5,531), the cardiovascular outcomes trial, finished in June 2026. The LIVERAGE liver trials run far longer — LIVERAGE (NCT06632444) to Dec 2031 and LIVERAGE-Cirrhosis (NCT06632457) to Jun 2029 |
| HRS-7535 / KAI-7535 (oral) — | | GLP-1 | Phase 3 | 11.1%50 wk · obesity · efficacy estimand · raw change | China weight-management filing planned this year, per Hengrui's own 8 Jul 2026 announcement; the global Phase 2 in the US and Australia reads out in 2027 |
| petrelintide — | | amylin | Phase 3 (started) | 10.7%42 wk · obesity · raw change | Nearer data points than the Phase 3: full results of ZUPREME-2, the Phase 2 in type 2 diabetes (NCT06926842), which Zealand says will be presented at a scientific conference after the 7 Oct 2026 topline; and ZYNERGY, a Phase 2 of petrelintide combined with Roche's enicepatide (NCT07589686, n=486, estimated start 30 Sep 2026). The Phase 3 trials read out at week 64 at the earliest; no date given. (TBD) |
| elecoglipron (AZD5004 / ECC5004) — |  | GLP-1 | Phase 3 | 10.5%26 wk · obesity, no T2D · raw change | Embold and Eluminate Phase 3 readouts (2027-2028) |
| efpeglenatide — |  | GLP-1 | Filed · Korea | 9.8%40 wk · obesity, no T2D · raw change | Korean MFDS decision — the filing itself was completed 18 Dec 2025 and is under review |
| bofanglutide — | Gan & Lee Pharmaceuticals (Menarini for Europe) | GLP-1 | Phase 3 | — | Global phase 3 trial start (to support EU/US registration) (TBD) |
| brenipatide — | | GIPGLP-1 | Phase 3 | — | RENEW-ALC Phase 3 (AUD); earliest approval ~2028 |
| MET-233i (renamed PF-08653945) — | | amylin | Phase 2 | 8.4%5 wk · obesity · placebo-adjusted | SOLIS-1 Phase 2b combination readout (2027) |
| BI 3034701 — | | GLP-1GIPNPY2 | Phase 2 | — | Phase 2 primary completion (first efficacy data) (2027-08) |
| pemvidutide — |  | glucagonGLP-1 | Phase 2 complete | 15.6%48 wk · obesity · raw change | PERFORMA Phase 3 planned; no Phase 3 registered yet (2026-H2) |
| ABBV-295 (GUB014295) — |  | amylin | Phase 1 | 7.75%12 wk · mean BMI under 30, 88% men · raw change | Advancing toward Phase 2 (2026) |
| ACCG-2671 — | | amylin | Phase 1 | 3.3%Day 24 · healthy adults without obesity · single 10 mg dose, raw change | Phase 1/2a MAD topline data (12-week multiple ascending dose portion, adults with obesity, incl. a GLP-1-combination cohort) (2027-H1) |
| AZD6234 — | | amylin | Phase 2 complete | — | AZD9550 + AZD6234 combination readout (2026-H2) |
| HM17321 (LA-UCN2) — | Hanmi Pharmaceutical / Genentech (Roche) | UCN2 | Phase 1 | — | Phase 1 completion (NCT07219589); Genentech assumes development from Phase 2 |
| HRS-1596 — | Hengrui Pharma / Novo Nordisk (rights outside mainland China, Hong Kong, Macao and Taiwan) | GIPGLP-1 | Phase 1 (China approved to initiate; no patient dosed yet) | — | First Phase 1 dosing in China (approved but not yet started); deal expected to close Q4 2026, subject to Hart-Scott-Rodino antitrust clearance |
| PF-08642534 (YP05002) — | Pfizer (licensed from YaoPharma) | GLP-1 | Pre-Phase 3 | — | First efficacy data (TBD) |
These percentages are not a league table. Each is the highest-dose mean result at the approved (or trial) obesity dose, but the conditions differ — read the small print under each number. Trials vary in length (5 to 80 weeks) and in population (with or without type 2 diabetes), and the result is calculated in more than one way. Raw change is the change from baseline; placebo-adjusted subtracts the placebo group. Beyond that, sponsors report an idealised estimate of what happens if you stay on the drug — Lilly calls it the efficacy estimand, Novo the trial-product estimand — and a second figure that includes people who stopped or switched, labelled treatment-regimen or treatment-policy depending on the trial. The first will usually read higher than the second. Those two labels are not strictly interchangeable; each trial defines its own, so treat them as a family rather than one thing. Two drugs are only comparable when duration, population and calculation method all match. Diabetes brands and lower doses come in below the figure shown; see each drug's card for the per-product breakdown.
Recent updates
- Oct 8, 2026UBT251's China Phase 2 obesity trial was published: 13.6% to 19.7% weight loss at 24 weeks against 2.0% on placebo, in 205 young adults without diabetes. Two China Phase 3 trials are now recruiting.
- Oct 8, 2026Petrelintide's Phase 2 trial in people with type 2 diabetes reported: 7.4% to 9.2% weight loss at 28 weeks against 2.0% on placebo, with a small drop in HbA1c.
- Oct 7, 2026Added AMPLIFY, the three Phase 3 trials Lilly plans for EloraTZP, its eloralintide and tirzepatide combination in one injection. None is registered yet.
- Oct 7, 2026Viking started Part 2 of its VK2735 maintenance study, which tests tablets and less frequent injections after 21 weeks of weekly shots. Results are expected in 2027.
- Oct 2, 2026Added ATTAIN-NOW, Lilly's Phase 3 trial of orforglipron in people who are overweight but not obese. It asks whether the pill delays obesity, type 2 diabetes, high blood pressure or abnormal cholesterol over two years.
The pipeline moves fast. I keep this current.
Every trial readout and FDA decision, tracked. Get the updates in your inbox. Free, no spam.
Subscribe on Substack